$TGTX
TG THERAPEUTICS, INC.

2021 Q4 Form 10-Q Financial Statement

#000155837021015039 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $2.321M $2.030M $1.545M
YoY Change 5702.5% 5242.11% 3965.79%
Cost Of Revenue $210.0K $292.0K $148.0K
YoY Change
Gross Profit $2.111M $1.738M $1.397M
YoY Change
Gross Profit Margin 90.95% 85.62% 90.42%
Selling, General & Admin $32.41M $34.90M $34.02M
YoY Change -26.1% -1.12% 135.67%
% of Gross Profit 1535.39% 2008.0% 2435.0%
Research & Development $62.65M $51.97M $44.87M
YoY Change 45.82% 2.98% 23.11%
% of Gross Profit 2967.6% 2990.05% 3211.95%
Depreciation & Amortization $80.00K $76.00K $66.00K
YoY Change 60.0% 52.0% 120.0%
% of Gross Profit 3.79% 4.37% 4.72%
Operating Expenses $95.06M $87.16M $79.04M
YoY Change 9.49% 1.63% 55.33%
Operating Profit -$92.95M -$85.13M -$77.49M
YoY Change -0.69% 52.41%
Interest Expense -$1.079M $1.038M $1.623M
YoY Change -16.36% -35.53% -27.15%
% of Operating Profit
Other Income/Expense, Net $688.0K -$509.0K -$1.005M
YoY Change -558.67% -64.68% -50.71%
Pretax Income -$93.34M -$85.64M -$78.50M
YoY Change 5.8% -1.75% 48.44%
Income Tax
% Of Pretax Income
Net Earnings -$93.34M -$85.64M -$78.50M
YoY Change 5.8% -1.75% 48.43%
Net Earnings / Revenue -4021.46% -4218.57% -5080.71%
Basic Earnings Per Share -$0.65
Diluted Earnings Per Share -$704.1K -$647.0K -$594.3K
COMMON SHARES
Basic Shares Outstanding 142.9M 142.8M 141.5M
Diluted Shares Outstanding 132.4M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $314.8M $356.9M $443.5M
YoY Change -48.01% 40.38% 60.91%
Cash & Equivalents $298.9M $326.5M $401.7M
Short-Term Investments $15.88M $30.34M $41.75M
Other Short-Term Assets $2.884M $2.502M $2.950M
YoY Change 166.3% 290.33% 92.06%
Inventory
Prepaid Expenses
Receivables $1.389M $1.384M $931.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $331.0M $371.8M $455.1M
YoY Change -45.9% 42.81% 61.98%
LONG-TERM ASSETS
Property, Plant & Equipment $600.0K $600.0K $597.0K
YoY Change 24.74% 58.73% 80.36%
Goodwill $799.0K $799.0K $799.0K
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $35.53M $24.55M $12.76M
YoY Change
Other Assets $1.264M $1.263M $1.261M
YoY Change -2.77% -2.85% -3.0%
Total Long-Term Assets $48.66M $37.91M $26.33M
YoY Change 250.05% 180.36% 92.44%
TOTAL ASSETS
Total Short-Term Assets $331.0M $371.8M $455.1M
Total Long-Term Assets $48.66M $37.91M $26.33M
Total Assets $379.6M $409.7M $481.4M
YoY Change -39.32% 49.6% 63.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $51.29M $44.70M $40.23M
YoY Change 38.63% 28.82% 35.45%
Accrued Expenses $11.60M $14.33M $10.01M
YoY Change 14.88% 113.82% 96.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $975.0K $16.00M $23.16M
YoY Change -95.6% 9.66% 221.64%
Total Short-Term Liabilities $65.38M $87.66M $87.55M
YoY Change -25.32% 12.86% 29.63%
LONG-TERM LIABILITIES
Long-Term Debt $66.79M $0.00 $0.00
YoY Change 765.58% -100.0% -100.0%
Other Long-Term Liabilities $10.30M $10.52M $10.72M
YoY Change -6.33% 0.14% 1.12%
Total Long-Term Liabilities $66.79M $10.52M $10.72M
YoY Change 765.58% -30.24% -51.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $65.38M $87.66M $87.55M
Total Long-Term Liabilities $66.79M $10.52M $10.72M
Total Liabilities $142.5M $98.17M $98.27M
YoY Change 34.04% -4.87% -2.12%
SHAREHOLDERS EQUITY
Retained Earnings -$1.329B -$1.200B -$1.100B
YoY Change 35.5% 34.47% 36.61%
Common Stock $143.0K $143.0K $143.0K
YoY Change 1.42% 10.85% 12.6%
Preferred Stock
YoY Change
Treasury Stock (at cost) $234.0K $234.0K $234.0K
YoY Change 17.0% 0.0% 0.0%
Treasury Stock Shares $41.31K $41.31K $41.31K
Shareholders Equity $237.2M $311.5M $383.1M
YoY Change
Total Liabilities & Shareholders Equity $379.6M $409.7M $481.4M
YoY Change -39.32% 49.6% 63.4%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$93.34M -$85.64M -$78.50M
YoY Change 5.8% -1.75% 48.43%
Depreciation, Depletion And Amortization $80.00K $76.00K $66.00K
YoY Change 60.0% 52.0% 120.0%
Cash From Operating Activities -$86.91M -$67.20M -$60.16M
YoY Change 67.04% 18.88% 37.27%
INVESTING ACTIVITIES
Capital Expenditures -$80.00K -$79.00K -$172.0K
YoY Change -50.0% -12.22% 330.0%
Acquisitions
YoY Change
Other Investing Activities $3.368M -$552.0K -$2.297M
YoY Change -106.49% -103.68% -120.42%
Cash From Investing Activities $3.288M -$631.0K -$2.479M
YoY Change -106.31% -104.23% -122.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 56.00M -7.361M -7.157M
YoY Change -86.12% -120.87% -102.97%
NET CHANGE
Cash From Operating Activities -86.91M -67.20M -60.16M
Cash From Investing Activities 3.288M -631.0K -2.479M
Cash From Financing Activities 56.00M -7.361M -7.157M
Net Change In Cash -27.62M -75.19M -69.80M
YoY Change -109.23% 1084.14% -133.48%
FREE CASH FLOW
Cash From Operating Activities -$86.91M -$67.20M -$60.16M
Capital Expenditures -$80.00K -$79.00K -$172.0K
Free Cash Flow -$86.83M -$67.12M -$59.99M
YoY Change 67.4% 18.93% 37.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001001316
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32639
dei Entity Registrant Name
EntityRegistrantName
TG THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort Street, 9th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
554-4484
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TGTX
dei Trading Symbol
TradingSymbol
TGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
142943139
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326512000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553439000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
30338000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
51987000
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1384000
CY2021Q3 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
11043000
CY2020Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
5231000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2502000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1083000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
371779000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
611740000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1263000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1259000
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
24550000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8804000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9312000
CY2021Q3 tgtx Leasehold Interest
LeaseholdInterest
1892000
CY2020Q4 tgtx Leasehold Interest
LeaseholdInterest
2051000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
600000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
481000
CY2021Q3 us-gaap Goodwill
Goodwill
799000
CY2020Q4 us-gaap Goodwill
Goodwill
799000
CY2021Q3 us-gaap Assets
Assets
409687000
CY2020Q4 us-gaap Assets
Assets
625642000
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
44702000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
37014000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12628000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18236000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
15999000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
22179000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1468000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1669000
CY2021Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
12858000
CY2020Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
8456000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
87655000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
87554000
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
495000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
610000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7716000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10020000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1360000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-5293000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-27545000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-114000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10412000
CY2021Q3 us-gaap Liabilities
Liabilities
98170000
CY2020Q4 us-gaap Liabilities
Liabilities
106292000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142984448
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
140617606
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142943139
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
140576297
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
143000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
141000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1546967000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1500040000
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1235359000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-980597000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
311517000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
519350000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
409687000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
625642000
CY2021Q3 us-gaap Revenues
Revenues
2030000
CY2020Q3 us-gaap Revenues
Revenues
38000
us-gaap Revenues
Revenues
4368000
us-gaap Revenues
Revenues
114000
CY2021Q3 tgtx Cost Of Product Revenue
CostOfProductRevenue
292000
tgtx Cost Of Product Revenue
CostOfProductRevenue
580000
CY2021Q3 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
4534000
CY2020Q3 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
4618000
tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
19061000
tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
8150000
CY2021Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
47433000
CY2020Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
45846000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
140872000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
114785000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51967000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50464000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159933000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122935000
CY2021Q3 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
9463000
CY2020Q3 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
23712000
tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
27857000
tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
38618000
CY2021Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
25436000
CY2020Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
11584000
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
67821000
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
25373000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34899000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35296000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
95678000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
63991000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
87158000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
85760000
us-gaap Operating Expenses
OperatingExpenses
256191000
us-gaap Operating Expenses
OperatingExpenses
186926000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-85128000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-85722000
us-gaap Operating Income Loss
OperatingIncomeLoss
-251823000
us-gaap Operating Income Loss
OperatingIncomeLoss
-186812000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1038000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1610000
us-gaap Interest Expense
InterestExpense
4559000
us-gaap Interest Expense
InterestExpense
5038000
CY2021Q3 us-gaap Other Income
OtherIncome
529000
CY2020Q3 us-gaap Other Income
OtherIncome
169000
us-gaap Other Income
OtherIncome
1619000
us-gaap Other Income
OtherIncome
687000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-509000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1441000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2940000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4351000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-85637000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-87163000
us-gaap Profit Loss
ProfitLoss
-254763000
us-gaap Profit Loss
ProfitLoss
-191163000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.70
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
132353119
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
119176336
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
132109912
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
112380784
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
519350000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2021Q1 tgtx Offering Costs
OfferingCosts
-183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
16618000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-90628000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
445285000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2021Q2 tgtx Offering Costs
OfferingCosts
10900000
CY2021Q2 tgtx Offering Costs At Market
OfferingCostsAtMarket
1400000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
16304000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-78497000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
383130000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000
CY2021Q3 tgtx Offering Costs
OfferingCosts
-22000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
13996000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-85637000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
311517000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38615000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11068000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-51116000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-51116000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1353000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
165042000
CY2020Q2 tgtx Offering Costs At Market
OfferingCostsAtMarket
500000
CY2020Q2 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
76036000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7370000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-52884000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
194227000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2020Q3 tgtx Offering Costs
OfferingCosts
10900000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-1000
CY2020Q3 tgtx Offering Costs At Market
OfferingCostsAtMarket
2000000.0
CY2020Q3 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
35227000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
28330000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-87163000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
170658000
us-gaap Profit Loss
ProfitLoss
-254763000
us-gaap Profit Loss
ProfitLoss
-191163000
us-gaap Share Based Compensation
ShareBasedCompensation
46918000
us-gaap Share Based Compensation
ShareBasedCompensation
46768000
us-gaap Depreciation
Depreciation
202000
us-gaap Depreciation
Depreciation
105000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
421000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
75000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
694000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
694000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
159000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
163000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1422000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1364000
tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
315000
tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-286000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
7255000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2503000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1384000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
12090000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
5893000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1507000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
202000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3620000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27566000
us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-14590000
tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
276303000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
216000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
135000
tgtx Repayment Of Offering Costs
RepaymentOfOfferingCosts
204000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254154000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
1263000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
1257000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
327775000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
255411000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-114000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-208725000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-162481000
tgtx Proceeds From Maturities
ProceedsFromMaturities
40000000
tgtx Proceeds From Maturities
ProceedsFromMaturities
35250000
tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
43299000
tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
7482000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
321000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14578000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
276438000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-226923000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
141523000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554698000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113888000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
327775000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
255411000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326512000
us-gaap Interest Paid Net
InterestPaidNet
2698000
us-gaap Interest Paid Net
InterestPaidNet
3447000
CY2020Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
200000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
700000
CY2021Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
400000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
381400000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1200000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13126038
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11103701
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13126038
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11103701
CY2021Q3 tgtx Revenue Gross
RevenueGross
2528000
tgtx Revenue Gross
RevenueGross
5167000
CY2021Q3 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
292000
us-gaap Administrative Fees Expense
AdministrativeFeesExpense
487000
CY2021Q3 tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
128000
tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
222000
CY2021Q3 tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
103000
tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
179000
CY2021Q3 tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
13000
tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
25000
CY2021Q3 tgtx Gross To Net Adjustments
GrossToNetAdjustments
536000
tgtx Gross To Net Adjustments
GrossToNetAdjustments
913000
CY2021Q3 tgtx Net Product Revenue
NetProductRevenue
1992000
tgtx Net Product Revenue
NetProductRevenue
4254000
CY2021Q3 tgtx Gross Net Accruals
GrossNetAccruals
400000
CY2021Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
54888000
CY2021Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
4000
CY2021Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
13000
CY2021Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
54879000
CY2020Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
51987000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
1000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
4000
CY2020Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
51984000
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
623000
CY2021Q3 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
623000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
938000
CY2020Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
938000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
938000
tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
764000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1079000
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
623000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
14000000.0
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
28300000
us-gaap Share Based Compensation
ShareBasedCompensation
46900000
us-gaap Share Based Compensation
ShareBasedCompensation
46800000
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
147058
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.08
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
300000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1468000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1669000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10020000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10412000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11488000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12081000
CY2021Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
30000000
CY2020Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
30000000
CY2021Q3 tgtx End Of Term Fee
EndOfTermFee
975000
CY2020Q4 tgtx End Of Term Fee
EndOfTermFee
975000
CY2021Q3 tgtx Long Term Debt Gross
LongTermDebtGross
30975000
CY2020Q4 tgtx Long Term Debt Gross
LongTermDebtGross
30975000
CY2021Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
386000
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1080000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
30589000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
29895000
CY2021Q3 tgtx Long Term Debt Principal Payments
LongTermDebtPrincipalPayments
14590000
CY2021Q3 tgtx Long Term Debt Excluding Principal Payments
LongTermDebtExcludingPrincipalPayments
15999000
CY2020Q4 tgtx Long Term Debt Excluding Principal Payments
LongTermDebtExcludingPrincipalPayments
29895000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
15999000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
22179000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7716000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
532000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
534000
us-gaap Operating Lease Cost
OperatingLeaseCost
1595000
us-gaap Operating Lease Cost
OperatingLeaseCost
1611000
CY2021Q3 us-gaap Lease Cost
LeaseCost
532000
CY2020Q3 us-gaap Lease Cost
LeaseCost
534000
us-gaap Lease Cost
LeaseCost
1595000
us-gaap Lease Cost
LeaseCost
1611000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
505000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2035000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2040000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1924000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1653000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
9889000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18046000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6558000
CY2021Q3 tgtx Operating Lease Liability Incremental Borrowing Rate
OperatingLeaseLiabilityIncrementalBorrowingRate
11488000

Files In Submission

Name View Source Status
0001558370-21-015039-index-headers.html Edgar Link pending
0001558370-21-015039-index.html Edgar Link pending
0001558370-21-015039.txt Edgar Link pending
0001558370-21-015039-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgtx-20210930.xsd Edgar Link pending
tgtx-20210930x10q.htm Edgar Link pending
tgtx-20210930x10q_htm.xml Edgar Link completed
tgtx-20210930xex31d1.htm Edgar Link pending
tgtx-20210930xex31d2.htm Edgar Link pending
tgtx-20210930xex32d1.htm Edgar Link pending
tgtx-20210930xex32d2.htm Edgar Link pending
tgtx-20210930_cal.xml Edgar Link unprocessable
tgtx-20210930_def.xml Edgar Link unprocessable
tgtx-20210930_lab.xml Edgar Link unprocessable
tgtx-20210930_pre.xml Edgar Link unprocessable